Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial by Vermeire S et al.
 Newcastle University ePrints 
 
Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, 
Feagan BG, Panes J, Salas A, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, 
Tew GW, Luca D, Tang MT, Diehl L, Eastham-Anderson J, De Hertogh G, 
Perrier C, Egen JG, Kirby JA, van Assche G, Rutgeerts P. Etrolizumab as 
induction therapy for ulcerative colitis: a randomised, controlled, phase 2 
trial. Lancet 2014, 384(9940), 309-318. 
Copyright: 
©2014 Vermeire et al. Open Access article distributed under the terms of CC BY-NC-ND license. 
The article is available at: 
http://dx.doi.org/10.1016/S0140-6736(14)60661-9 
Date deposited:  29-08-2014 
 
 
 
This work is licensed under a  
Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License 
 
 ePrints – Newcastle University ePrints 
http://eprint.ncl.ac.uk 
 
Articles
www.thelancet.com   Vol 384   July 26, 2014 309
Etrolizumab as induction therapy for ulcerative colitis: 
a randomised, controlled, phase 2 trial
Séverine Vermeire, Sharon O’Byrne, Mary Keir, Marna Williams, Timothy T Lu, John C Mansfi eld, Christopher A Lamb, Brian G Feagan, Julian Panes, 
Azucena Salas, Daniel C Baumgart, Stefan Schreiber, Iris Dotan, William J Sandborn, Gaik W Tew, Diana Luca, Meina T Tang, Lauri Diehl, 
Jeff rey Eastham-Anderson, Gert De Hertogh, Clementine Perrier, Jackson G Egen, John A Kirby, Gert van Assche, Paul Rutgeerts
Summary
Background Etrolizumab is a humanised monoclonal antibody that selectively binds the β7 subunit of the heterodimeric 
integrins α4β7 and αEβ7. We aimed to assess etrolizumab in patients with moderately-to-severely active ulcerative colitis.
Methods In this double-blind, placebo-controlled, randomised, phase 2 study, patients with moderately-to-severely active 
ulcerative colitis who had not responded to conventional therapy were recruited from 40 referral centres in 11 countries. 
Eligible patients (aged 18–75 years; Mayo Clinic Score [MCS] of 5 of higher [or ≥6 in USA]; and disease extending 25 cm 
or more from anal verge) were randomised (1:1:1) to one of two dose levels of subcutaneous etrolizumab (100 mg at 
weeks 0, 4, and 8, with placebo at week 2; or 420 mg loading dose [LD] at week 0 followed by 300 mg at weeks 2, 4, and 8), 
or matching placebo. The primary endpoint was clinical remission at week 10, defi ned as MCS of 2 or less (with no 
individual subscore of >1), analysed in the modifi ed intention-to-treat population (mITT; all randomly assigned patients 
who had received at least one dose of study drug, had at least one post-baseline disease-activity assessment, and had a 
centrally read screening endoscopic subscore of ≥2). This study is registered with ClinicalTrials.gov, number 
NCT01336465.
Findings Between Sept 2, 2011, and July 11, 2012, 124 patients were randomly assigned, of whom fi ve had a endoscopic 
subscore of 0 or 1 and were excluded from the mITT population, leaving 39 patients in the etrolizumab 100 mg group, 
39 in the etrolizumab 300 mg plus LD group, and 41 in the placebo group for the primary analyses. No patients in the 
placebo group had clinical remission at week 10, compared with eight (21% [95% CI 7–36]) patients in the etrolizumab 
100 mg group (p=0·0040) and four (10% [0·2–24]) patients in the 300 mg plus LD group (p=0·048). Adverse events 
occurred in 25 (61%) of 41 patients in the etrolizumab 100 mg group (fi ve [12%] of which were regarded as serious), 
19 (48%) of 40 patients in the etrolizumab 300 mg plus LD group (two [5%] serious), and 31 (72%) of 43 patients in 
the placebo group (fi ve [12%] serious).
Interpretation Etrolizumab was more likely to lead to clinical remission at week 10 than was placebo. Therefore, 
blockade of both α4β7 and αEβ7 might provide a unique therapeutic approach for the treatment of ulcerative colitis, 
and phase 3 studies have been planned.
Funding Genentech.
Copyright © Vermeire et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Ulcerative colitis is a chronic infl ammatory disease 
characterised by an aberrant immunological response to 
microbial antigens in genetically predisposed 
individuals.1 Immunomodulators (azathioprine, merca-
ptopurine, and tumour necrosis factor [TNF] antagonists 
[infl iximab, adalimumab, golimumab]) are used in 
patients who do not respond to therapy with 
aminosalicylates and corticosteroids; however, these 
agents do not work in many patients, and non-selective 
immune suppression is associated with an increased risk 
of serious infection and cancer.2,3
Inhibition of the interaction of the α4β7 integrin with its 
ligand, mucosal addressin cell adhesion molecule-1 
(MAdCAM-1), interferes with immune-cell traffi  cking into 
the intestine and is an eff ective therapy for both ulcerative 
colitis and Crohn’s disease.4–6 Furthermore, this selective 
treatment approach avoids broad-spectrum immuno-
suppression. Etrolizumab, a humanised mono clonal 
antibody that selectively binds the β7 subunit of both the 
α4β77,8 and αEβ79 integrin heterodimers, antagonises 
α4β7-MAdCAM-1-mediated egress of lympho cytes from 
the mucosal vasculature and αEβ7-E-cadherin interactions 
that are believed to be involved in retention of αEβ7 cells 
in the intraepithelial compartment.9–11
We assessed the effi  cacy and safety of etrolizumab in 
patients with moderately or severely active ulcerative 
colitis.
Methods
Study design and participants  
This parallel-group, double-blind, placebo-controlled, 
randomised, phase 2 study assessed patients with 
moderately-to-severely active ulcerative colitis who had 
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not responded to conventional therapy. Patients in the 
USA were required by the US Food and Drug 
Administration (FDA) to have not responded to both 
immunomodulators and TNF antagonists. Patients were 
recruited from 40 referral centres in 11 countries 
(Australia, Belgium, Canada, Czech Republic, Germany, 
Hungary, Israel, New Zealand, Spain, UK, and USA).
Eligible patients were aged 18–75 years, with a diagnosis 
of ulcerative colitis and a Mayo Clinic Score12 (MCS) of 
5 points or higher (≥6 points in the USA as required by 
the FDA), a centrally read MCS endoscopic subscore of 
2 points or higher, a rectal bleeding subscore of 1 point or 
higher, and disease extending 25 cm or more from the 
anal verge. Patients had disease duration of 12 weeks or 
more, and doses had to be stable if they were receiving 
oral mesalazine (2·4–4·8 g per day), corticosteroids 
(≤20 mg per day of prednisone), azathioprine, 
mercaptopurine, or methotrexate. Tapering of con-
comitant immunomodulator therapy (USA only) and 
oral corticosteroids was mandated according to the 
defi ned protocol (appendix). Patients with an extensive 
colonic resection or colectomy, presence of an ileostomy 
or colostomy, risk factors for infection, major organ 
dysfunction, or disorders other than ulcerative colitis that 
might have needed treatment with more than 20 mg per 
day of prednisone were not eligible (appendix).
Institutional review boards at each study site approved 
the protocol and all patients provided written informed 
consent. The study was undertaken and reported in 
accordance with the study protocol.
Randomisation and masking  
Patients were randomly assigned in a 1:1:1 ratio via an 
interactive voice and web response system to one of two 
dose levels of subcutaneous etrolizumab or matching 
placebo. Randomisation was balanced through 
stratifi cation according to the following hierarchy: 
concomitant treatment with corticosteroids, immuno-
modulators, previous TNF antagonist exposure, and study 
site. All patients, assessing physicians, the funder and its 
agents, and study personnel were masked to treatment 
assignment, except for the site pharmacists who prepared 
the study drug but who did not interact with the patient. 
Both etrolizumab and placebo appeared as a transparent 
fl uid within the syringes to maintain masking.
Procedures  
Patients were assigned either to subcutaneous etrolizumab 
(Genentech, South San Francisco, CA, USA) at 100 mg at 
weeks 0, 4, and 8, with placebo at week 2 (etrolizumab 
100 mg group), to etrolizumab 420 mg at week 0 followed 
by 300 mg at weeks 2, 4, and 8 (etrolizumab 300 mg plus 
loading dose [LD] group), or to matching placebo. Patients 
who had a disease fl are, defi ned as a 2-point increase from 
the time of remission in the partial MCS with 3 days of 
continuous rectal bleeding confi rmed by fl exible 
sigmoidoscopy with an endoscopy subscore of 2 points or 
higher, were permitted to receive rescue therapy consisting 
of an increase in corticosteroids, mesalazine, or immuno-
modulators. Use of TNF antagonists, ciclosporin, or 
tacrolimus was not permitted.
Assessments done before randomisation and at regular 
intervals throughout the study period included physical 
examination, safety assessments, MCS, electro cardio-
gram, haematology and serum chemistries, serum for 
pharmacokinetic analysis, antidrug antibody tests, stool 
sample analysis for faecal calprotectin, colonic biopsies 
for biomarker analysis by quantitative PCR, and 
immunohistochemistry (see schedule of assessments 
and protocol in the appendix). Flow cytometry was 
undertaken on the peripheral blood of all patients and on 
the colonic biopsy samples of a subgroup of patients. 
Flow cytometry assays used competing and non-
competing antibodies to allow for detection of β7-
expressing cells in the tissue or peripheral circulation 
(appendix).
Outcomes
The primary endpoint was clinical remission at week 10, 
defi ned as the proportion of patients with MCS of 
2 points or less with no individual subscore of greater 
than 1 point. Secondary endpoints were clinical remission 
at week 6, clinical response (3-point decrease and 30% 
reduction in MCS and 1-point decrease or more in rectal 
bleeding subscore or absolute rectal bleeding subscore of 
0 or 1), and the achievement of both an endoscopic 
subscore of 0 and a rectal bleeding subscore of 0 at 
weeks 6 and 10. Exploratory outcomes included changes 
from baseline in mucosal healing (endoscopic subscore 
of 0 or 1), histological active disease severity score,13 and 
pharmacodynamic biomarkers in the peripheral blood 
(β7 occupancy and expression on T and B lymphocyte 
subsets) and colonic tissue (β7 occupancy and expression 
on T-lymphocyte subsets, quantifi cation of αE+ cells, and 
cytokine and adhesion molecule gene expression). We 
did an exploratory diagnostic analysis of gene expression 
and immunohistochemistry in baseline colonic biopsy 
samples.
Statistical analysis  
We estimated that randomisation of 120 patients would 
provide 80% power to detect a 25% diff erence in the 
proportion of patients in clinical remission between 
either etrolizumab dose group and placebo, under the 
assumption of a two-sided type I error rate of 0·2 and a 
placebo remission rate of 20%. We used a conservative 
estimate of 20% instead of the 15% remission rate 
reported in the placebo group of the ACT1 study.2
We used descriptive statistics to summarise diff erences 
in demographic and baseline characteristics. We assessed 
effi  cacy in the modifi ed intention-to-treat (mITT) 
population, which included all randomly assigned 
patients who received at least one dose of study drug, had 
at least one post-baseline disease-activity assessment, 
See Online for appendix
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and had a centrally read screening endoscopic subscore 
of 2 points or higher. We compared primary and 
secondary endpoints with the Cochran-Mantel-Haenszel 
χ² test, with adjustment for stratifi cation variables. 
Patients who discontinued the study before week 10 and 
those who received rescue therapy before week 10 were 
classifi ed as non-responders. Patients with sample 
collection that was incomplete or of insuffi  cient quality 
were excluded from the pharmacodynamic analysis.
Subgroup analyses of the primary endpoint were done 
in the subsets of patients defi ned by the stratifi cation 
variables using Fisher’s exact test. Sites within countries 
were grouped according to geographical region: eastern 
European (Hungary and Czech Republic) versus non-
eastern European countries (USA, Canada, UK, 
Belgium, Germany, Spain, Israel, Australia, and New 
Zealand). We did post-hoc subgroup analyses of the 
eff ect of αE (ITGAE) levels on clinical remission using 
median cutoff  values in baseline colonic biopsy samples 
to defi ne high and low αE levels. We compared changes 
from baseline in the pharmacodynamic covariates 
between each of the two etrolizumab groups and the 
placebo group, and between the patients who had 
achieved clinical remission and those who had not in the 
etrolizumab group, with the use of the Wilcoxon signed 
rank test. p values were not adjusted for multiple 
comparisons and should be interpreted with caution. We 
assessed safety in all randomly assigned patients using 
descriptive statistics.
This study is registered with ClinicalTrials.gov, number 
NCT01336465.
Role of the funding source  
The funder of the study was involved in the study design 
and the data collection and analysis. All authors had full 
access to all the data in the study, made the decision to 
submit these data for publication, were involved in 
writing the manuscript, and agreed upon the fi nal 
content of the paper. The study funder provided funding 
for editorial assistance with manuscript preparation. The 
corresponding author had fi nal responsibility for the 
decision to submit for publication.
Results
Between Aug 23, 2011, and July 11, 2012, 187 patients 
were assessed for eligibility (fi gure 1). Of the 124 randomly 
assigned patients, 41 were assigned to receive etrolizumab 
100 mg, 40 to etrolizumab 300 mg plus LD, and 43 to 
placebo. Five patients had a centrally read screening 
endoscopic subscore of 0 or 1 and were excluded from 
the mITT population, leaving 39 patients in the 
etrolizumab 100 mg group, 39 in the etrolizumab 300 mg 
Figure 1: Trial profi le
LD=loading dose. mITT=modifi ed intention-to-treat.
187 assessed for eligibility
124 randomly assigned
41 assigned and received etrolizumab 
 100 mg
43 assigned and received placebo
41 analysed (mITT population)
 2 excluded from analysis (central
endoscopic score <2)
39 analysed (mITT population)
 2 excluded from analysis (central
endoscopic score <2)
39 analysed 
 1 excluded from analysis (central
endoscopic score <2)
27 discontinued at week 10
 0 adverse events
 0 protocol violation
 27 lack of efficacy
 9 discontinued after week 10
 7 adverse events
 2 lack of efficacy
19 discontinued at week 10
 1 adverse events
 0 protocol violation
 18 lack of efficacy
 9 discontinued after week 10
 5 adverse events
 4 lack of efficacy
23 discontinued at week 10
 0 adverse events
 1 protocol violation
 22 lack of efficacy
 7 discontinued after week 10
 6 adverse events
 1 lack of efficacy
 2 discontinued before 
week 10 owing to 
adverse events
 3 discontinued before
week 10 owing to 
adverse events
 1 discontinued before
week 10 owing to 
adverse events
40 assigned and received etrolizumab 
 300 mg plus LD
63 excluded
 62 did not meet inclusion criteria
 1 outside randomisation window
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plus LD group, and 41 in the placebo group for the 
primary analyses. Within each country the enrolment 
was balanced between the treatment groups (appendix). 
Baseline characteristics were generally similar between 
the treatment groups, with the exception of sex, age, 
bodyweight, and concomitant treatment with mesalazine 
(table 1; appendix). The pooled etrolizumab treatment 
groups contained a higher proportion of men than did 
the placebo group (64% [52 of 81] vs 44% [19 of 43]). Mean 
age was higher in the etrolizumab 100 mg group than in 
the placebo group. Mean bodyweight was higher in the 
etrolizumab 100 mg group than in the etrolizumab 
300 mg plus LD group and the placebo group. A greater 
proportion of patients in the placebo group received 
concomitant treatment with mesalazine than did patients 
in the etrolizumab groups (table 1).
In the mITT population at week 10, none of 41 patients 
in the placebo group were in clinical remission compared 
with eight (21% [95% CI 7–36]) of 39 patients in the 
etrolizumab 100 mg group (p=0·0040) and four (10% 
[0·2–24]) of 39 patients in the etrolizumab 300 mg plus 
LD group (p=0·048; fi gure 2A). 
For the secondary endpoints, no signifi cant treatment 
group diff erences were noted for clinical remission at 
week 6, with two (5%) of 41 patients in the placebo group 
in clinical remission compared with four (10%) of 
39 patients in the etrolizumab 100 mg group (p=0·66) 
and three (8%) of 39 in the etrolizumab 300 mg plus LD 
group (p=0·97; fi gure 2A). 14 (34%) of 41 patients in the 
placebo group had a clinical response at week 6 compared 
with 19 (49%) of 39 patients in the etrolizumab 100 mg 
group (p=0·27) and 15 (38%) of 39 in the etrolizumab 
300 mg plus LD group (p=0·68). At week 10, 12 (29%) of 
41 patients in the placebo group had a clinical response 
compared with 13 (33%) of 39 in the etrolizumab 100 mg 
group (p=0·83) and 12 (31%) of 39 patients in the 
etrolizumab 300 mg plus LD group (p=0·90; fi gure 2B). 
One (2%) patient in the placebo group had simultaneous 
endoscopic and rectal bleeding subscores of 0 at week 6 
compared with three (8%) of 39 patients in the 
etrolizumab 100 mg group (p=0·96) and one (3%) of 39 
in the 300 mg plus LD group (p=0·59; fi gure 2C). At 
week 10, no patients in the placebo group had 
simultaneous endoscopic and rectal bleeding subscores 
of 0 compared with four (10%) of 39 patients in the 
etrolizumab 100 mg group (p=0·16) and three (8%) of 39 
in the 300 mg plus LD group (p=0·19; fi gure 2C). The 
proportions of patients with MCS subscores of 1 point or 
less, and those with subscores of 0 points, were, 
numerically, generally higher in patients in the 
etrolizumab groups than in those in the placebo group 
(appendix).
The proportions of patients in each treatment group 
who achieved clinical remission at week 10 when 
analysed by stratifi cation variables (concomitant steroid 
use, concomitant immunomodulator use, previous TNF 
antagonist exposure, and study site) showed a similar 
trend to that reported in the overall study population, but 
with a greater diff erence between the etrolizumab 100 mg 
group and placebo group for patients taking steroids, 
those not taking immunomodulators, and those naive to 
TNF antagonists (fi gure 3; appendix). A greater diff erence 
between the etrolizumab 100 mg group and placebo 
group was also noted in those who live in eastern Europe; 
however, this diff erence was not signifi cant owing to the 
small sample size (p=0·055). In the subgroup of patients 
who were naive to TNF antagonists, seven (44%) of 
16 patients in the etrolizumab 100 mg group (p=0·0068 
when compared with none of 15 in the placebo group) 
and three (25%) of 12 patients in the etrolizumab 300 mg 
plus LD group (p=0·0752 vs placebo group) were in 
clinical remission at week 10. In the subgroup of patients 
who had previously not responded to treatment with 
TNF antagonists, one (5%) of 22 patients in the 
etrolizumab 100 mg group (p=0·47) and one (4%) of 
25 in the etrolizumab 300 mg plus LD group (p=1·00) 
were in clinical remission at week 10 (fi gure 3).
In the exploratory analyses, six (15%) of 41 patients in 
the placebo group had mucosal healing at week 10, 
compared with ten (26%) of 39 in the etrolizumab 100 mg 
group (p=0·32) and eight (21%) of 39 in the etrolizumab 
300 mg plus LD group (p=0·82; appendix). 
Histopathology active disease score decreased from 
baseline to week 10 in patients in the etrolizumab 100 mg 
group, but the decrease was not signifi cant (p=0·099; 
Etrolizumab 
100 mg (n=41)
Etrolizumab 
300 mg + LD 
(n=40)
Placebo (n=43)
Age, years 44·4 (13·9) 40·3 (13·4) 37·5 (12·8)
Male 28 (68%) 24 (60%) 19 (44%)
White 38 (93%) 38 (95%) 41 (95%)
Bodyweight, kg 88·8 (29·9) 74·8 (17·1) 74·2 (19·7)
Duration of ulcerative colitis, years 9·2 (8·3) 8·0 (7·1) 9·8 (8·4) 
Concomitant medication use
Corticosteroids 17 (41%) 18 (45%) 20 (47%) 
Dose, mg/day 13·1 (6·0) 14·5 (5·7) 13·7 (6·6) 
Immunosuppressants 17 (41%) 14 (35%) 16 (37%) 
Mesalazine 28 (68%) 25 (63%) 38 (88%)
Previous anti-TNF therapy 25 (61%) 28 (70%) 27 (63%) 
No response to previous anti-TNF therapy 24 (59%) 26 (65%) 26 (60%) 
Unacceptable adverse event 1 (2%) 2 (5%) 1 (2%)
Disease extent
Rectosigmoid 10 (24%) 8 (20%) 13 (30%) 
Left sided 14 (34%) 14 (35%) 17 (40%) 
Pancolitis or extensive 15 (37%) 18 (45%) 13 (30%) 
Non-specifi ed 2 (5%) 0 0
Mayo Clinic Score 9·3 (1·5) 9·2 (1·6) 9·1 (1·9)
CRP, mg/dL 1·4 (2·4) 1·8 (2·6) 1·4 (1·9) 
Faecal calprotectin, μg/g 1547·0 (1808·5) 1301·3 (1482·6) 1087·8 (1118·1)
Data are mean (SD) or number (%). LD=loading dose. TNF=tumour necrosis factor. CRP=C-reactive protein.
Table 1: Patient demographics and baseline characteristics in all randomly assigned patients 
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appendix). In the mITT population, CRP concentration 
decreased in both etrolizumab groups compared with the 
placebo group from baseline to week 10 (data not shown). 
In the subgroup of patients with raised CRP 
(>0·4 mg/dL), CRP concentration in only the etrolizumab 
300 mg plus LD group decreased compared with placebo; 
however, this diff erence was not signifi cant (appendix).
Etrolizumab displayed linear pharmacokinetic profi les. 
Exposure for the etrolizumab 300 mg plus LD group was 
about 4·4 times higher than that for the etrolizumab 
100 mg group (appendix). At week 10, the mean 
etrolizumab serum concentration was 8·52 mg/mL 
(SD 4·76) for the etrolizumab 100 mg group (n=34) and 
37·8 mg/mL (16·9) for the etrolizumab 300 mg plus LD 
group (n=38). A drug concentration quartile versus 
response (clinical remission at week 10) analysis did not 
show an exposure–response correlation (appendix).
Of 81 patients assigned to either etrolizumab group 
with available blood samples, four (5%) patients had 
detectable antidrug antibodies after treatment (all were 
in the etrolizumab 100 mg group). One additional patient 
in the etrolizumab 100 mg group had detectable 
antibodies before receiving treatment and remained 
positive with consistent titres throughout the study. The 
number of adverse events did not seem to be associated 
with the presence of antidrug antibodies (data not 
shown). Additionally, a positive antidrug-antibody result 
did not have noticeable eff ect on etrolizumab serum 
concentrations in patients in either etrolizumab group 
(data not shown).
Etrolizumab maximally occupied β7 receptors on 
circulating CD4+ and CD8+β7+ T lymphocytes at both 
doses (p=0·0006 [etrolizumab 100 mg vs placebo] and 
p<0·0001 [etrolizumab 300 mg plus LD vs placebo]; 
appendix), with a corresponding specifi c increase in 
intestinal homing CD4+β7+ T lymphocytes in the 
peripheral blood (p=0·071 [etrolizumab 100 mg vs placebo] 
and p=0·0008 [etrolizumab 300 mg plus LD vs placebo]; 
appendix). We noted similar results with CD19+β7+ 
B lymphocytes (p<0·0001 for both etrolizumab 100 mg 
and 300 mg plus LD etrolizumab groups vs placebo; 
appendix). In the colonic mucosa, we also noted maximal 
occupancy of β7 receptors with etrolizumab 100 mg at 
week 6 (p=0·0043 vs placebo) and week 10 (p=0·0081), and 
Figure 2: Proportion of patients with clinical remission, clinical response, and endoscopic remission/rectal bleeding score of 0 in the mITT population
(A) Clinical remission at week 6 and week 10. (B) Clinical response (3-point decrease and 30% reduction in Mayo Clinic Score and 1-point decrease or more in rectal 
bleeding subscore or absolute rectal bleeding subscore of 0 or 1) at week 6 and week 10. (C) Endoscopic and rectal bleeding subscores of 0 at week 6 and week 10. 
LD=loading dose. mITT=modifi ed intention-to-treat. *p<0·05 (vs placebo). †p<0·01 (vs placebo).
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with etrolizumab 300 mg plus LD (p=0·0021 at week 6 vs 
placebo and p=0·0087 at week 10; appendix). However, 
there was no diff erence in the overall relative frequencies 
of mucosal β7-expressing CD3+CD4– T cells reported in 
patients in the etrolizumab groups compared with those 
in the placebo group (appendix). Similarly, no apparent 
change in β7, β1, or αE gene expression was identifi ed by 
quantitative PCR, whereas α4 gene expression in colonic 
tissue seemed to be reduced at week 10 in patients in the 
etrolizumab groups who achieved remission compared 
with those who did not (p=0·0284; appendix). On 
assessment of the intestinal lymphocyte compartments in 
colonic biopsy samples by immunohistochemistry, we 
noted a decreasing trend in the proportion of αE+ cells in 
the intestinal crypt epithelium in patients in the 
etrolizumab groups compared with those in the placebo 
group, and this was most pronounced in patients who 
achieved clinical remission at week 10 (appendix), with no 
apparent decrease in αE+ cells in the lamina propria 
(appendix). Additionally, expression of MAdCAM-1 was 
reduced in patients in the etrolizumab group who 
achieved clinical remission compared with those who did 
not (p=0·0019), as were infl ammatory cytokines 
(interleukin 17A, p=0·0084; interleukin 17F, p=0·0215; 
interleukin 23, p=0·0088; interleukin 1β, p=0·0041; TNFα, 
p=0·0126; interleukin 6, p=0·0008; and interleukin 12p40, 
p=0·15) and lymphocyte gene expression (CD19, 
p=0·0039; CD4, p=0·051; CD8, p=0·14; CD3 p=0·14; 
appendix). By contrast, expression of E-cadherin in biopsy 
samples increased in patients in the etrolizumab groups 
who achieved clinical remission compared with those who 
did not (p=0·0022; appendix).
In a post-hoc analysis, more patients in the etrolizumab 
100 mg group who had high αE (ITGAE) gene expression 
in their baseline colonic biopsy sample achieved clinical 
remission at 10 weeks than did those with low αE gene 
expression (using a median cutoff  value to defi ne high 
and low expression; fi gure 4A; appendix). Additionally, 
baseline colonic biopsy samples showed a range of αE+ 
cells per total cells, with improved clinical remission in 
patients with high numbers of αE+ cells, defi ned by a 
median cutoff  (fi gures 4B; appendix). Baseline 
characteristics were balanced across treatment groups in 
the subgroups of patients defi ned by baseline colonic 
biopsy sample αE (ITGAE) gene expression (appendix).
Patients in the etrolizumab 100 mg group had higher 
rates of rash, infl uenza-like illness, and arthralgias than 
did those in the placebo or etrolizumab 300 mg plus LD 
groups; all of these events were regarded as mild to 
Figure 4: Clinical remission according to baseline colonic biopsy αE levels
(A) Clinical remission according to gene expression of integrin αE, as measured by quantitative PCR, in the colonic biopsy sample taken at baseline. (B) Clinical 
remission according to levels of αE+ cells in the colonic biopsy sample taken at baseline. LD=loading dose. TNF=tumour necrosis factor.
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Placebo
(n=43)
Any adverse event 25 (61%) 19 (48%) 31 (72%)
Serious adverse events 5 (12%) 2 (5%) 5 (12%)
Serious infections 0 0 1 (2%)
Adverse events occurring in ≥5% of any treatment group
Ulcerative colitis 7 (17%) 9 (23%) 8 (19%)
Nausea 2 (5%) 2 (5%) 2 (5%)
Nasopharyngitis 4 (10%) 6 (15%) 8 (19%)
Fatigue 2 (5%) 2 (5%) 4 (9%)
Asthenia 0 0 4 (9%)
Infl uenza-like illness 3 (7%) 0 1 (2%)
Nervous system disorders 6 (15%) 4 (10%) 6 (14%)
Headache 5 (12%) 4 (10%) 5 (12%)
Dizziness 1 (2%) 0 3 (7%)
Arthralgia 6 (15%) 2 (5%) 4 (9%)
Cough 2 (5%) 2 (5%) 2 (5%)
Rash 3 (7%) 1 (3%) 1 (2%)
Iron-defi ciency anaemia 0 2 (5%) 2 (5%)
Data are number of patients with one or more event (% of patients). *All 
randomly assigned patients received at least one dose of study treatment.
Table 2: Adverse events in the safety population (all randomly assigned 
patients)*
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moderate in severity (table 2). Serious adverse events 
were reported in 12 patients (table 2); fi ve of these were 
related to ulcerative colitis (two in the etrolizumab 
100 mg group; one in the etrolizumab 300 mg plus LD 
group; and two in the placebo group; appendix). No 
serious opportunistic infections were reported. Mild 
injection site reactions occurred in four patients in the 
etrolizumab 300 mg plus LD group and in two patients 
in the placebo group.
Discussion
Etrolizumab at both doses studied signifi cantly improved 
clinical remission at 10 weeks compared with placebo in 
patients with moderately or severely active ulcerative 
colitis. Most patients in this study (61%) had previously 
not responded to anti-TNF therapy and thus are 
representative of a refractory patient group. In support of 
this fact, no patient assigned to placebo achieved clinical 
remission. Clinical remission was mainly reported in 
patients who were naive to TNF antagonists. Although 
the comparison is indirect, the placebo-corrected 
proportion of patients in the etrolizumab 100 mg group 
who achieved clinical remission in our study (21%) 
seemed to be higher than the placebo-corrected 
proportion of patients in the vedolizumab group who 
achieved clinical remission in a phase 2 study (18·5%) in 
a less refractory patient population who were naive to 
anti-TNF therapy and not taking concomitant cortico-
steroids or immuno suppressants.4 
Additionally, our study is, to the best of our knowledge, 
the fi rst prospective, randomised, placebo-controlled trial 
in which a centrally read MCS endoscopy subscore of at 
least 2 was an eligibility requirement, to better ensure 
that the patients included had moderately or severely 
active disease. As opposed to clinical remission, for 
which the total MCS needs to be 2 or lower (ie, most of 
the four subscores need to be 0 with only two subscores 
of 1 point or one subscore of 2 points), clinical response 
requires a 3-point decrease and 30% reduction in MCS 
and a 1-point decrease or more in rectal bleeding subscore 
or absolute rectal bleeding subscore of 0 or 1. Therefore, 
if the patients selected for the study had a total baseline 
MCS of 9–12 points (the mean in this study for all groups 
combined was 9·2 [SD 1·7]), they could fulfi l the criteria 
for clinical response while continuing to have an MCS 
suggestive of clinically signifi cant ongoing disease. In 
our study, a relatively high proportion of patients in the 
placebo group achieved a clinical response—probably 
because, as noted in the previous sentence, this endpoint 
is less rigorous—and this proportion did not signifi cantly 
diff er from those in the etrolizumab groups. By contrast, 
endoscopic remission (ie, endoscopic score of 0) is an 
extremely rigorous endpoint, especially for the treatment-
refractory patients included in this study, and thus was 
achieved in a small proportion of actively treated patients 
compared with no patients in the placebo group. The 
defi nition of mucosal healing (endoscopic score 0 or 1) is 
less restrictive than that of endoscopic remission, with 
more patients meeting this endpoint at week 10 across all 
treatment groups. The patients who had previously not 
responded to anti-TNF therapy in this study were a 
particularly refractory patient population (21% did not 
respond to more than one anti-TNF). Although we noted 
no benefi t for this subgroup of patients at week 10 in this 
induction study, this fi nding was also noted in a larger 
phase 3 study6 of vedolizumab, in which patients who 
had not responded to anti-TNF therapy did not 
signifi cantly benefi t at induction at week 6, although they 
did improve after 52 weeks of therapy.
Adverse events occurred at a similar frequency in the 
three treatment groups. No patients developed progressive 
multifocal leukoencephalopathy, an adverse event that 
has been associated with the non-selective anti-α4 integrin 
antibody natalizumab. The risk of progressive multifocal 
leukoencephalopathy with etrolizumab is expected to be 
negligible in view of the selectivity of the β7 receptor for 
the mucosal epithelium. However, the safety profi le for 
etrolizumab thus far is based on short-term induction 
studies with low patient numbers and will be further 
assessed in larger trials with longer-term dosing.
Panel: Research in context
Systematic review
We searched PubMed for clinical trials of existing and emerging 
biological therapies for moderately-to-severely active ulcerative 
colitis using the search terms “ulcerative colitis treatment” and 
“moderate to severe” published between Jan 1, 2000, and 
Feb 28, 2014. The search was limited to positive, phase 1–3 
clinical trials and trials were included if they were of therapies, 
not procedures, and included adult patients with moderate to 
severe ulcerative colitis who were outpatients (studies that 
included patients with severe ulcerative colitis admitted to 
hospital were excluded). We found that etrolizumab was one of 
nine therapies (including infl iximab, adalimumab, golimumab, 
vedolizumab, AMG 181, PF-00547659, BMS-936557, and 
tofacitinib) that have entered or completed phase 2 and phase 
3 clinical trials for the treatment of ulcerative colitis.
Interpretation
Our study is, to the best of our knowledge, the fi rst 
double-blind, randomised, placebo-controlled trial of 
etrolizumab in patients with moderately-to-severely active 
ulcerative colitis. Patients who received etrolizumab were 
more likely to have clinical remission at week 10 than were 
patients who received placebo, and etrolizumab was well 
tolerated. During treatment with etrolizumab, β7 receptors 
were fully occupied in the peripheral blood and in the colonic 
tissue. Patients with higher levels of αE expression in the 
colonic tissue were more likely to achieve clinical remission 
than patients with lower levels. These results support further 
long-term study to investigate the potential of etrolizumab 
to bring clinically meaningful benefi t to patients with 
moderately-to-severely active ulcerative colitis. 
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Importantly, the lowest serum concentration of 
etrolizumab associated with full colonic tissue occupancy 
reported in this study was 1·7 μg/mL, a concentration 
similar to the EC90 value (1·26 μg/mL) for receptor 
occupancy in the peripheral blood.14 Thus, in this trial of 
patients with moderately or severely active ulcerative 
colitis, the serum concentration of etrolizumab required to 
occupy β7 receptors in the colonic mucosa was similar to 
that required for occupancy in the peripheral blood. 
Furthermore, the low subcutaneous dose of etrolizumab 
100 mg was suffi  cient to maximally occupy β7 receptors in 
both the blood and the colonic mucosa, and hence might 
have contributed to the signifi cant clinical benefi t reported. 
Although we noted maximum β7 occupancy in both 
etrolizumab dose cohorts, and did not detect any apparent 
exposure–response relation in the quartile-concentration 
response analysis, patients in the etrolizumab 300 mg plus 
LD group did seem to have reduced clinical remission 
when compared with those who received the 100 mg 
monthly dose. Etrolizumab treatment might alter cellular 
migration of diff erent cell types (eg, regulatory T cells) in a 
dose-dependent manner. Identifi cation of human 
regulatory T cells by gene expression is not straightforward, 
because genes expressed by regulatory T cells, such as 
FOXP3, are also expressed by activated T cells.15 We noted 
no signifi cant change in gene expression of FOXP3 
between the two etrolizumab dose groups or between the 
etrolizumab groups and placebo (data not shown). More 
specifi c regulatory-T-cell markers, such as epigenetic 
modifi cations at the FOXP3 locus, would have to be 
assessed prospectively in a subsequent study. Although we 
made every eff ort to ensure that the treatment groups were 
well balanced with respect to demographics, baseline 
characteristics, and concomitant medications for ulcerative 
colitis, some unknown imbalance in patients could have 
possibly led to the dose response reported. Similarly, 
although the numbers of patients per treatment group 
(about 40) are adequate for a phase 2 proof-of-concept 
study, we cannot rule out that the attenuated eff ect in the 
higher dose group was a by-chance observation. In support 
of this interpretation, an analysis of the MCS by subscore 
of 1 point or less or 0 points across the dose groups showed 
an inconsistent eff ect of dose (appendix).
Consistent with the role of β7 receptors in mediation of 
lymphocyte traffi  cking to the intestine, there was a 
corresponding increased frequency of β7-expressing 
lymphocytes in the peripheral blood. The proportion of 
α4β7 versus αEβ7 T cells in the peripheral blood was not 
specifi cally assessed in this study; however, exploratory 
analysis in healthy volunteers and patients with 
infl ammatory bowel disease has shown that the 
concentrations of αEβ7 T cells in peripheral blood are too 
low to track by fl ow cytometry and most to all β7+ cells in 
the periphery are α4β7+ (unpublished data). By contrast, 
in our colonic substudy, α4 expression was assessed and 
all β7+ cells were found to coexpress αE and α4. Although 
maximal β7 occupancy was noted in both the peripheral 
circulation and, in a representative patient subgroup, in 
the colonic mucosa for a minimum of 10 weeks in our 
study, a clinical benefi t was not found in all patients, 
suggesting that the infl ammatory process continues in 
some patients despite blockade of the β7 receptor. This 
fi nding could be explained by the proinfl ammatory 
activity of immune cells already present in the gut before 
treatment with etrolizumab, or a potential β7-independent 
mechanism of leucocyte traffi  cking to the intestinal 
mucosa. Further understanding of alternative 
mechanisms of infl ammation will require exploration in 
patients undergoing long-term therapy with etrolizumab.
Although mucosal proinfl ammatory cytokine 
expression decreased in patients in the etrolizumab 
groups who achieved clinical remission, expression of 
E-cadherin increased. E-cadherin has been shown to be 
expressed at lower concentrations in patients with 
infl ammatory bowel disease than in healthy controls,16 
suggesting that the observed increase in E-cadherin is 
related to mucosal healing in these patients. This fi nding 
is supported by the improvement in the histological 
active disease severity score in patients who received 
etrolizumab in our study.
The results from the post-hoc exploratory diagnostic 
analysis done in this phase 2 study provide an indication 
of possible heterogeneity in treatment benefi t for patients 
with varying αE concentration. Additional prospective 
studies involving larger groups of patients are necessary 
to confi rm these fi ndings. If validated, these results 
suggest two possible hypotheses: αE+ cells themselves 
contribute to the pathogenesis of ulcerative colitis; or αE 
expression is correlated with the activity of a pathogenic 
pathway that is inhibited by etrolizumab treatment. With 
respect to the former hypothesis, αE and αE-expressing 
cells have been reported to have several roles in the 
regulation of immune responses.17 In-vitro studies of both 
mouse and human cells have shown that αEβ7+ dendritic 
cells can imprint T cells with a gut-homing phenotype and 
induce regulatory T-cell diff erentiation.18–20,21 Additionally, 
αE has been suggested to be a marker of distinct regulatory 
T-cell subpopulations,22,23 although the function of αE in 
regulating the activity of this cell type is unclear.24 By 
contrast, results of several studies in both human beings 
and animal models have shown that αE-expressing 
lymphocytes can produce proinfl ammatory cytokines, and 
disrupting αE function in mice can ameliorate intestinal 
infl ammation.25–29 Our fi ndings—that baseline colonic αE 
expression could improve response to etrolizumab and 
that treatment with etrolizumab reduced αE+ cell 
association with the intestinal epithelium—suggest that 
αEβ7+ lymphocytes contribute to the pathobiology of 
ulcerative colitis. Hence, blockade of both α4β7 and αEβ7 
function might provide a unique therapeutic approach for 
the treatment of this disease. Further prospective studies 
will be important to better elucidate the eff ect of 
etrolizumab on the traffi  cking and function of various 
α4β7-expressing and αEβ7-expressing immune cells. 
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